Edwards Lifesciences (EW) News
NYSE: EWHealth CareIndustrial SpecialtiesUSD
85.21+0.97 (+1.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
EW news summary
We found 31 recent headlines mentioning Edwards Lifesciences (EW): 3 in the past week and 9 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, EW is up 1.15% at $85.21. The most recent story, "Barclays Initiates Coverage of Edwards Lifesciences at Overweight", was published by Nasdaq on Oct 7, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Edwards Lifesciences headlines
- Barclays Initiates Coverage of Edwards Lifesciences at OverweightFintel reports that on October 7, 2026, Barclays initiated coverage of Edwards Lifesciences (NYSE:EW) (SWX:EW) with a Overweight recommendation.Edwards Lifesciences Corporation, based in the United…NasdaqEW, BCS
- Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTechSeeking AlphaEW, BCS, SYK
- Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.NasdaqISRG, EW, GKOS
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic…NasdaqABBV, AZN, CBLL, CDXS
- Edwards Secures FDA Approval For First Adjustable Pulmonary Valve For Children(RTTNews) - Edwards Lifesciences (EW) announced that the U.S. FDA has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed for pediatric patients with congenital heart…Nasdaq
- Edwards Wins FDA Approval For First Pediatric Surgical Pulmonary Valve(RTTNews) - Thursday, Edwards Lifesciences (EW) announced that the U.S. FDA approved the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for pediatric patients…Nasdaq
- Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity AheadA Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian…Nasdaq
- Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking AlphaEW, DB
- Edwards Lifesciences (EW) Shares Cross Below 200 DMAIn trading on Friday, shares of Edwards Lifesciences Corp (Symbol: EW) crossed below their 200 day moving average of $84.97, changing hands as low as $83.81 per share. Edwards Lifesciences Corp…Nasdaq
- Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To CompoundSeeking Alpha
- Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqPACB, EW
- Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.NasdaqISRG, EW, GKOS
- Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqIQV, EW
- MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.NasdaqMDT, BSX, EW
- Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.NasdaqSTE, SYK, EW
- Should Investors Buy STERIS as Growth Meets Reasonable Valuation?STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.NasdaqSTE, SYK, EW
- Should You Hold Edwards Lifesciences Stock in Your Portfolio?EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.NasdaqEW, TFX, GMED, VCYT
- Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.NasdaqEW, ABT, BSX
- Edwards Climbs 14% in 3 Months as Growth Strength Tests ValuationEdwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.NasdaqEW, BSX, MDT
- Edwards Lifesciences: Strong Execution, But Little Room For Error At $90Seeking Alpha
- Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything ElseSeeking Alpha
- Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Edwards Lifesciences Has Everything Investors Want Except ValueSeeking Alpha
- Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaEW, BAC
- Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Edwards Lifesciences: More Appeal For The HeartSeeking Alpha
- Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking AlphaEW, BCS
- Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha
- Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day TranscriptSeeking Alpha
- Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call TranscriptSeeking Alpha